Routine magnetic resonance imaging for idiopathic olfactory loss: A modeling-based economic evaluation

Luke Rudmik, Kristine A. Smith, Zachary M. Soler, Rodney J. Schlosser, Timothy Smith

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

IMPORTANCE: Idiopathic olfactory loss is a common clinical scenario encountered by otolaryngologists. While trying to allocate limited health care resources appropriately, the decision to obtain a magnetic resonance imaging (MRI) scan to investigate for a rare intracranial abnormality can be difficult. OBJECTIVE: To evaluate the cost-effectiveness of ordering routine MRI in patients with idiopathic olfactory loss. DESIGN, SETTING, AND PARTICIPANTS: We performed a modeling-based economic evaluation with a time horizon of less than 1 year. Patients included in the analysis had idiopathic olfactory loss defined by no preceding viral illness or head trauma and negative findings of a physical examination and nasal endoscopy. INTERVENTIONS: Routine MRI vs no-imaging strategies. MAIN OUTCOMES AND MEASURES: We developed a decision tree economic model from the societal perspective. Effectiveness, probability, and cost data were obtained from the published literature. Litigation rates and costs related to a missed diagnosis were obtained from the Physicians Insurers Association of America. A univariate threshold analysis and multivariate probabilistic sensitivity analysis were performed to quantify the degree of certainty in the economic conclusion of the reference case. The comparative groups included those who underwent routine MRI of the brain with contrast alone and those who underwent no brain imaging. The primary outcome was the cost per correct diagnosis of idiopathic olfactory loss. RESULTS: The mean (SD) cost for the MRI strategy totaled $2400.00 ($1717.54) and was effective 100% of the time, whereas the mean (SD) cost for the no-imaging strategy totaled $86.61 ($107.40) and was effective 98%of the time. The incremental cost-effectiveness ratio for the MRI strategy compared with the no-imaging strategy was $115 669.50, which is higher than most acceptable willingness-to-pay thresholds. The threshold analysis demonstrated that when the probability of having a treatable intracranial disease process reached 7.9%, the incremental cost-effectiveness ratio for MRI vs no imaging was $24 654.38. The probabilistic sensitivity analysis demonstrated that the no-imaging strategy was the cost-effective decision with 81%certainty at a willingness-to-pay threshold of $50 000. CONCLUSIONS AND RELEVANCE: This economic evaluation suggests that the most cost-effective decision is to not obtain a routine MRI scan of the brain in patients with idiopathic olfactory loss. Outcomes from this study may be used to counsel patients and aid in the decision-making process.

Original languageEnglish (US)
Pages (from-to)911-917
Number of pages7
JournalJAMA Otolaryngology - Head and Neck Surgery
Volume140
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Cost-Benefit Analysis
Magnetic Resonance Imaging
Costs and Cost Analysis
Economic Models
Insurance Carriers
Decision Trees
Health Resources
Brain
Jurisprudence
Craniocerebral Trauma
Nose
Neuroimaging
Endoscopy
Physical Examination
Decision Making
Multivariate Analysis
Economics
Outcome Assessment (Health Care)
Delivery of Health Care
Physicians

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery
  • Medicine(all)

Cite this

Routine magnetic resonance imaging for idiopathic olfactory loss : A modeling-based economic evaluation. / Rudmik, Luke; Smith, Kristine A.; Soler, Zachary M.; Schlosser, Rodney J.; Smith, Timothy.

In: JAMA Otolaryngology - Head and Neck Surgery, Vol. 140, No. 10, 01.10.2014, p. 911-917.

Research output: Contribution to journalArticle

Rudmik, Luke ; Smith, Kristine A. ; Soler, Zachary M. ; Schlosser, Rodney J. ; Smith, Timothy. / Routine magnetic resonance imaging for idiopathic olfactory loss : A modeling-based economic evaluation. In: JAMA Otolaryngology - Head and Neck Surgery. 2014 ; Vol. 140, No. 10. pp. 911-917.
@article{d6e662920b214db8a702b435f8a85b43,
title = "Routine magnetic resonance imaging for idiopathic olfactory loss: A modeling-based economic evaluation",
abstract = "IMPORTANCE: Idiopathic olfactory loss is a common clinical scenario encountered by otolaryngologists. While trying to allocate limited health care resources appropriately, the decision to obtain a magnetic resonance imaging (MRI) scan to investigate for a rare intracranial abnormality can be difficult. OBJECTIVE: To evaluate the cost-effectiveness of ordering routine MRI in patients with idiopathic olfactory loss. DESIGN, SETTING, AND PARTICIPANTS: We performed a modeling-based economic evaluation with a time horizon of less than 1 year. Patients included in the analysis had idiopathic olfactory loss defined by no preceding viral illness or head trauma and negative findings of a physical examination and nasal endoscopy. INTERVENTIONS: Routine MRI vs no-imaging strategies. MAIN OUTCOMES AND MEASURES: We developed a decision tree economic model from the societal perspective. Effectiveness, probability, and cost data were obtained from the published literature. Litigation rates and costs related to a missed diagnosis were obtained from the Physicians Insurers Association of America. A univariate threshold analysis and multivariate probabilistic sensitivity analysis were performed to quantify the degree of certainty in the economic conclusion of the reference case. The comparative groups included those who underwent routine MRI of the brain with contrast alone and those who underwent no brain imaging. The primary outcome was the cost per correct diagnosis of idiopathic olfactory loss. RESULTS: The mean (SD) cost for the MRI strategy totaled $2400.00 ($1717.54) and was effective 100{\%} of the time, whereas the mean (SD) cost for the no-imaging strategy totaled $86.61 ($107.40) and was effective 98{\%}of the time. The incremental cost-effectiveness ratio for the MRI strategy compared with the no-imaging strategy was $115 669.50, which is higher than most acceptable willingness-to-pay thresholds. The threshold analysis demonstrated that when the probability of having a treatable intracranial disease process reached 7.9{\%}, the incremental cost-effectiveness ratio for MRI vs no imaging was $24 654.38. The probabilistic sensitivity analysis demonstrated that the no-imaging strategy was the cost-effective decision with 81{\%}certainty at a willingness-to-pay threshold of $50 000. CONCLUSIONS AND RELEVANCE: This economic evaluation suggests that the most cost-effective decision is to not obtain a routine MRI scan of the brain in patients with idiopathic olfactory loss. Outcomes from this study may be used to counsel patients and aid in the decision-making process.",
author = "Luke Rudmik and Smith, {Kristine A.} and Soler, {Zachary M.} and Schlosser, {Rodney J.} and Timothy Smith",
year = "2014",
month = "10",
day = "1",
doi = "10.1001/jamaoto.2014.1883",
language = "English (US)",
volume = "140",
pages = "911--917",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Routine magnetic resonance imaging for idiopathic olfactory loss

T2 - A modeling-based economic evaluation

AU - Rudmik, Luke

AU - Smith, Kristine A.

AU - Soler, Zachary M.

AU - Schlosser, Rodney J.

AU - Smith, Timothy

PY - 2014/10/1

Y1 - 2014/10/1

N2 - IMPORTANCE: Idiopathic olfactory loss is a common clinical scenario encountered by otolaryngologists. While trying to allocate limited health care resources appropriately, the decision to obtain a magnetic resonance imaging (MRI) scan to investigate for a rare intracranial abnormality can be difficult. OBJECTIVE: To evaluate the cost-effectiveness of ordering routine MRI in patients with idiopathic olfactory loss. DESIGN, SETTING, AND PARTICIPANTS: We performed a modeling-based economic evaluation with a time horizon of less than 1 year. Patients included in the analysis had idiopathic olfactory loss defined by no preceding viral illness or head trauma and negative findings of a physical examination and nasal endoscopy. INTERVENTIONS: Routine MRI vs no-imaging strategies. MAIN OUTCOMES AND MEASURES: We developed a decision tree economic model from the societal perspective. Effectiveness, probability, and cost data were obtained from the published literature. Litigation rates and costs related to a missed diagnosis were obtained from the Physicians Insurers Association of America. A univariate threshold analysis and multivariate probabilistic sensitivity analysis were performed to quantify the degree of certainty in the economic conclusion of the reference case. The comparative groups included those who underwent routine MRI of the brain with contrast alone and those who underwent no brain imaging. The primary outcome was the cost per correct diagnosis of idiopathic olfactory loss. RESULTS: The mean (SD) cost for the MRI strategy totaled $2400.00 ($1717.54) and was effective 100% of the time, whereas the mean (SD) cost for the no-imaging strategy totaled $86.61 ($107.40) and was effective 98%of the time. The incremental cost-effectiveness ratio for the MRI strategy compared with the no-imaging strategy was $115 669.50, which is higher than most acceptable willingness-to-pay thresholds. The threshold analysis demonstrated that when the probability of having a treatable intracranial disease process reached 7.9%, the incremental cost-effectiveness ratio for MRI vs no imaging was $24 654.38. The probabilistic sensitivity analysis demonstrated that the no-imaging strategy was the cost-effective decision with 81%certainty at a willingness-to-pay threshold of $50 000. CONCLUSIONS AND RELEVANCE: This economic evaluation suggests that the most cost-effective decision is to not obtain a routine MRI scan of the brain in patients with idiopathic olfactory loss. Outcomes from this study may be used to counsel patients and aid in the decision-making process.

AB - IMPORTANCE: Idiopathic olfactory loss is a common clinical scenario encountered by otolaryngologists. While trying to allocate limited health care resources appropriately, the decision to obtain a magnetic resonance imaging (MRI) scan to investigate for a rare intracranial abnormality can be difficult. OBJECTIVE: To evaluate the cost-effectiveness of ordering routine MRI in patients with idiopathic olfactory loss. DESIGN, SETTING, AND PARTICIPANTS: We performed a modeling-based economic evaluation with a time horizon of less than 1 year. Patients included in the analysis had idiopathic olfactory loss defined by no preceding viral illness or head trauma and negative findings of a physical examination and nasal endoscopy. INTERVENTIONS: Routine MRI vs no-imaging strategies. MAIN OUTCOMES AND MEASURES: We developed a decision tree economic model from the societal perspective. Effectiveness, probability, and cost data were obtained from the published literature. Litigation rates and costs related to a missed diagnosis were obtained from the Physicians Insurers Association of America. A univariate threshold analysis and multivariate probabilistic sensitivity analysis were performed to quantify the degree of certainty in the economic conclusion of the reference case. The comparative groups included those who underwent routine MRI of the brain with contrast alone and those who underwent no brain imaging. The primary outcome was the cost per correct diagnosis of idiopathic olfactory loss. RESULTS: The mean (SD) cost for the MRI strategy totaled $2400.00 ($1717.54) and was effective 100% of the time, whereas the mean (SD) cost for the no-imaging strategy totaled $86.61 ($107.40) and was effective 98%of the time. The incremental cost-effectiveness ratio for the MRI strategy compared with the no-imaging strategy was $115 669.50, which is higher than most acceptable willingness-to-pay thresholds. The threshold analysis demonstrated that when the probability of having a treatable intracranial disease process reached 7.9%, the incremental cost-effectiveness ratio for MRI vs no imaging was $24 654.38. The probabilistic sensitivity analysis demonstrated that the no-imaging strategy was the cost-effective decision with 81%certainty at a willingness-to-pay threshold of $50 000. CONCLUSIONS AND RELEVANCE: This economic evaluation suggests that the most cost-effective decision is to not obtain a routine MRI scan of the brain in patients with idiopathic olfactory loss. Outcomes from this study may be used to counsel patients and aid in the decision-making process.

UR - http://www.scopus.com/inward/record.url?scp=84908702858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908702858&partnerID=8YFLogxK

U2 - 10.1001/jamaoto.2014.1883

DO - 10.1001/jamaoto.2014.1883

M3 - Article

C2 - 25211179

AN - SCOPUS:84908702858

VL - 140

SP - 911

EP - 917

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 10

ER -